-
关于我们
Proji Company was founded in August 2004. It is a high-tech research and development enterprise established by returned overseas students, undertaking the task of industrializing and transforming various scientific research projects. -
Scientific research technology
Scientific research technology
科研技术
Proji Company is a constituent unit of the "National Engineering Research Center for Protein Technology" of Tsinghua University. It is the first national engineering laboratory established by the National Development and Reform Commission at Tsinghua University. Former President of the Chinese Academy of Sciences, Zhou Guangzhao, and the "Father of DNA", Nobel laureate James D. Watson served as honorary directors of the laboratory, with Professor Luo Yongzhang serving as the director. -
Products
公司产品
For nearly two decades, Proji Company has been primarily engaged in the development and production of recombinant protein drugs, antibody drugs, and in-vitro diagnostic reagents. It has established a unique R&D and large-scale preparation technology platform for recombinant protein drugs that has reached international standards. -
Project
项目公司
The company has long received strong support from various levels of government, including the National Development and Reform Commission, the Ministry of Science and Technology, and the municipal governments of Beijing, Yantai, Shenzhen, and Changzhou. -
新闻资讯
The company's marketing network spans 18 provinces and cities across the country (including 6 provinces and cities covered by medical insurance), benefiting more than 4 million patients, and gradually growing into a new benchmark in the biopharmaceutical industry. -
职业发展
From small-scale research institutions to advanced biopharmaceutical bases, the company's marketing network spans 18 provinces and cities across China.
Public Notice on Environmental Impact Assessment for the Expansion Project of Recombinant Human Albumin of Yantai Projiji Pharmaceutical Technology Co., Ltd.
Published Time:
2025-05-19 11:08
Yantai Progen Pharmaceutical Technology Co., Ltd.
Recombinant Human Albumin Expansion Project Project
Environmental Impact Assessment Public Notice
I. Project Overview
Total investment 100000 ten thousand yuan, the industry category is C2761 Biopharmaceutical manufacturing. The project is located in Wuxi Road, Yantai Economic and Technological Development Zone, Shandong Province 23 No. Progen Pharmaceutical Park, utilizing existing land, and newly built 4# Production workshop, comprehensive warehouse, outdoor methanol storage tank area, outdoor liquid oxygen storage tank area, while utilizing existing factory buildings ( 6 # Production workshop, 2# Production workshop) and the newly built 4# workshop to expand the production capacity of recombinant human albumin, and expand the sewage treatment plant structure on the idle land east of the existing sewage treatment plant, increase the sewage treatment capacity, and change the existing animal house to a finished product warehouse. Newly purchased fermentation systems and other domestically produced equipment about 150 sets. After completion, there will be a total of recombinant human albumin production lines in the factory area 3 lines, filling lines 2 lines, with an annual production capacity of 170 ten thousand recombinant human albumin.
II Environmental Impact Report The online link to the full text of the draft for soliciting opinions and the methods and channels for reviewing the paper version of the report:
Online link to the full text of the draft for soliciting opinions:
https://pan.baidu.com/s/1Rjaj1DBfCHw5taXS9Iq-pA?pwd=uefp Extraction code : uefp
Methods and channels for reviewing the paper version of the report: Wuxi Road, Yantai Economic and Technological Development Zone, Shandong Province 23 No. Progen Pharmaceutical Park ( B-34 Community).
III. Public Scope for Soliciting Opinions
Yantai Progen Pharmaceutical Technology Co., Ltd. Surrounding outward expansion 500m within the range.
IV. Online link to the public opinion form: http://www.mee.gov.cn/xxgk2018/xxgk/xxgk01/201810/t20181024_665329.html
V 、 Main methods for public opinion submission
You can contact the construction unit by phone email and other methods to express your opinions.
Construction unit: Wuxi Road, Yantai Economic and Technological Development Zone 23 No. Progen Pharmaceutical Park ( B-34 Community)
Contact person: Miao Gong, Contact number: 13306459143 ，Email: miaofubo@protgen.com ，Mailing address: Wuxi Road, Yantai Economic and Technological Development Zone, Shandong Province 23 No. Progen Pharmaceutical Park ( B-34 Community) 。
VI . Public Notice
If the public has any environmental protection opinions on the construction project, they can submit them to the construction unit within ten working days from the date of the public notice through the above contact methods, and can also send a copy of the written opinions to the local environmental protection administrative department.
Previous Page
Previous Page
Related Recommendations
Beijing Protgen Biotechnology Development Co., Ltd.
Tel:86010- 6297 9258
Postcode: 100085
Email:protgen@protgen.com
Address: No. 32, Chuangye Zhonglu, Haidian District, Beijing
Official Account QR Code
Maintenance Department QR Code
copyright © 2024 Beijing Progen Biotechnology Development Co., Ltd. Powered by：CEglobal TagsFriendly Links:Tsinghua UniversityNEC